xoma8k_040809.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C.  20549
 
 
FORM 8-K
 
 
CURRENT REPORT
 
 
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
 
Date of Report (Date of Earliest Event Reported):  April 8, 2009
 


XOMA LTD.
(Exact name of registrant as specified in its charter)
 
 
BERMUDA
(State or other jurisdiction of incorporation)


0-14710
  
52-2154066
(Commission File Number)
  
(IRS Employer Identification No.)
2910 Seventh Street, Berkeley, California
  
94710
(Address of principal executive offices)
  
(Zip code)
     
Registrant's telephone number, including area code
  
(510) 204-7200
 
 

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[   ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[   ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[   ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[   ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 


 

 
 
 


Item 8.01.                                Other Events.

On April 8, 2009, the U.S. Food and Drug Administration (the “FDA”) announced that Genentech, Inc. has begun a voluntary phased withdrawal of RAPTIVA® (efalizumab) from the United States market.  The FDA Statement is attached as Exhibit 1 hereto and incorporated by reference herein.


Item 9.01.                                Financial Statements and Exhibits.

1.           Statement issued by the FDA dated April 8, 2009

 

 
 
 
 

SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
Dated:  April 8, 2009
XOMA LTD.
 
By:  /s/ Christopher J. Margolin                          
Christopher J. Margolin
Vice President, General Counsel and Secretary



 

 
 
 
 

EXHIBIT INDEX
 
Number                      Description
 
1.
Statement issued by the FDA dated April 8, 2009